-+ 0.00%
-+ 0.00%
-+ 0.00%

US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.

Zhitongcaijing·11/09/2026 14:33:26
Listen to the news
US FDA: GLP-1 receptor agonists are required to change safety labels because they may increase the risk of rare but serious eye diseases.